167 related articles for article (PubMed ID: 36724417)
21. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
22. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
[TBL] [Abstract][Full Text] [Related]
23. OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma.
Raghavan SS; Mooney KL; Folpe AL; Charville GW
Hum Pathol; 2019 Sep; 91():77-85. PubMed ID: 31299267
[TBL] [Abstract][Full Text] [Related]
24. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
25. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
[TBL] [Abstract][Full Text] [Related]
26. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
[TBL] [Abstract][Full Text] [Related]
27. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
[TBL] [Abstract][Full Text] [Related]
28. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
29. Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma.
Dehner CA; Bell RC; Cao Y; He K; Chrisinger JSA; Armstrong AE; Yohe M; Shern J; Hirbe AC
JCO Precis Oncol; 2023 Sep; 7():e2300037. PubMed ID: 37738543
[TBL] [Abstract][Full Text] [Related]
30. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
[TBL] [Abstract][Full Text] [Related]
31. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
[TBL] [Abstract][Full Text] [Related]
32. Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.
Walther C; Mayrhofer M; Nilsson J; Hofvander J; Jonson T; Mandahl N; Øra I; Gisselsson D; Mertens F
Genes Chromosomes Cancer; 2016 Jan; 55(1):3-15. PubMed ID: 26482321
[TBL] [Abstract][Full Text] [Related]
33. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M
Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974
[TBL] [Abstract][Full Text] [Related]
34. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies.
Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R
Pediatr Blood Cancer; 2023 Dec; 70(12):e30701. PubMed ID: 37783659
[TBL] [Abstract][Full Text] [Related]
36. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
37. Histology and fusion status in rhabdomyosarcoma.
Rudzinski ER
Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
[TBL] [Abstract][Full Text] [Related]
39. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
[TBL] [Abstract][Full Text] [Related]
40. Metabolic response as assessed by
Harrison DJ; Chi YY; Tian J; Hingorani P; Mascarenhas L; McCowage GB; Weigel BJ; Venkatramani R; Wolden SL; Yock TI; Rodeberg DA; Hayes-Jordan AA; Teot LA; Spunt SL; Meyer WH; Hawkins DS; Shulkin BL; Parisi MT
Cancer Med; 2021 Feb; 10(3):857-866. PubMed ID: 33340280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]